• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV

    8/12/24 4:30:11 PM ET
    $ARYD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARYD alert in real time by email
    15-12G 1 ef20033769_1512g.htm 15-12G
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 15

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001‑40122
    ARYA SCIENCES ACQUISITION CORP IV
    (Exact name of registrant as specified in its charter)

    51 Astor Place, 10th Floor
    New York, New York 1003
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Class A Ordinary Shares, $0.0001 par value
    (Title of each class of securities covered by this Form)

    None
    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

    Rule 12g-4(a)(1)
    ☒
    Rule 12g-4(a)(2)
    ☐
    Rule 12h-3(b)(1)(i)
    ☒
    Rule 12h-3(b)(1)(ii)
    ☐
    Rule 15d-6
    ☐
    Rule 15d-22(b)
    ☐

    Approximate number of holders of record as of the certification or notice date: 1*

    *Effective July 31, 2024, in connection with the transactions contemplated by that certain Business Combination Agreement, dated as of February 13, 2024 (as amended by the Consent and Amendment No. 1 to Business Combination Agreement, dated as of June 25, 2024),  by and among ARYA Sciences Acquisition Corp IV (“ARYA”), Adagio Medical Holdings, Inc. (formerly known as Aja HoldCo, Inc.), Aja Merger Sub 1, Aja Merger Sub 2, Inc. and Adagio Medical, Inc., Aja Merger Sub 1 merged with and into ARYA Sciences Acquisition Corp IV, with ARYA Sciences Acquisition Corp IV surviving such merger as a wholly owned subsidiary of Adagio Medical Holdings, Inc.



    Pursuant to the requirements of the Securities Exchange Act of 1934, ARYA Sciences Acquisition Corp IV, has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     
    ARYA Sciences Acquisition Corp IV
       
    Date: August 12, 2024
    By:
    /s/ Olav Bergheim
     
    Name:
    Olav Bergheim
     
    Title:
    Director



    Get the next $ARYD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYD

    DatePrice TargetRatingAnalyst
    More analyst ratings